ATHA / Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference

Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (B more_horizontal

Athira Pharma, Inc. (ATHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined more_horizontal

Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (B more_horizontal

BOTHELL, Wash., March 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on deve more_horizontal

HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS HGF/MET small more_horizontal

Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration Fosgonimeton demonstrates improvement on diverse biomarkers of neurod more_horizontal

Athira Pharma has just read out first Phase 2 results in one of two Alzheimer's trials. Its drug candidate ATH-1017 targets the HGF/MET pathway, a uni more_horizontal

Athira Pharma, Inc. (ATHA) CEO Mark Litton on Q4 2021 Results - Earnings Call Transcript more_horizontal